Skip to main content

Table 1 Clinical characteristics of GO patients

From: The critical role of m6A methylation in the pathogenesis of Graves' ophthalmopathy

Patients ID Gender/age Months with GO Months with GD CAS Clinical subtype Smoking status TRAb (UI/l) TSH (μUI/ml) FT4 (ng/dl) Treatment for GD Treatment for GO
Use of ATD (actual) Cortico-steroids Cyclos-porine Surgical
A F/69 12 26 5 II 3.70 4.358 13.1 + + +
B F/63 20 43 4 II 2.73 3.137 17.93 + +
C F/40 6 10 5 II + 1.38 1.689 16.36 + + +
D F/52 9 9 6 II 7.34 0.079 17.33 + + + +
E M/57 6 20 3 II + 8.58 2.258 18.03 + + +
F M/35 7 30 3 II 5.33 2.512 14.23 + + +
G F/36 11 13 2 II 2.46 0.055 13.38 + + +
  1. GO = Graves' ophthalmopathy; GD = Graves' disease; CAS = Clinical Activity Score; TRAb = antibodies against TSH receptor; TSH = thyroid-stimulating hormone; FT4 = free thyroxine; ATD = anti-thyroid drug